SynthesisCPT: pharmacometrics & systems pharmacology2026
A Model-Based Meta-Analysis Framework Quantifying Drivers of Placebo Response in Atopic Dermatitis Trials.
Synthesis in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Model-Based Meta-Analysis Framework Quantifying Drivers of Placebo Response in Atopic Dermatitis Trials.CPT: pharmacometrics & systems pharmacology · 2026Pooled it
- Empowering Clinical Development With Disease Progression Modeling: Recommendations From the Clinical Trials Transformation Initiative.Clinical and translational science · 2026Article
- Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis.CPT: pharmacometrics & systems pharmacology · 2026Article
- Systematic Review and Model-Based Meta-Analysis of Targeted Drugs for Systemic Sclerosis.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Atopic dermatitis (AD) clinical trials exhibit substantial placebo response variability, confounding efficacy assessments of novel therapies. Traditional meta-analyses have identified potential contributors to this variability but rely on single time-point estimates, which fail to account for dynamic, longitudinal response patterns across trials. To overcome this limitation, we developed a model-based meta-analysis (MBMA) framework that characterizes time-course projections of EASI-75 placebo responses while accounting for key covariates. A systematic literature review identified 40 moderate-to-severe AD trials (18 Phase 2, 22 Phase 3), encompassing 4827 patients, suitable for longitudinal modeling. Modeling results highlighted concomitant therapy as a significant driver of placebo response, with trials permitting topical corticosteroids (TCS) demonstrating a 1.8-fold increase in EASI-75 placebo rates compared to trials without concomitant therapy. Additionally, baseline disease severity of the study population, as reflected by the mean baseline EASI score, was inversely associated with placebo response; each 1-point increase in baseline EASI reduced EASI-75 placebo rates at Weeks 12 and 16 by 0.96-fold. Time-course modeling suggested that placebo responses plateaued by Week 12, with EASI-75 outcomes at Week 12 capturing 94% of the projected response at Week 16. Overall, this MBMA framework provides quantitative guidance to optimize clinical trial design, refine power calculations, and improve the differentiation between therapeutic and placebo effects in AD drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.